# Hims & Hers (HIMS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/HIMS
## Company Profile
- Ticker: HIMS
- Exchange: NYSE
- Sector: Biopharma
- Location: United States
- Tags: Digital Health
## Stock Data
- Close: 27.82 USD
- Market cap: 6367401189.450001 USD
- Last updated: 2026-09-03
## Business Overview
Hims & Hers is a consumer telehealth company delivering direct-to-consumer care across hair loss, mental health, sexual health, and other self-pay categories.
## Why The Stock Is Moving

As of Sep 3, 2026, HIMS closed down 3.00% at $27.82. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in the United States and listed on NYSE, Hims sits in digital health and consumer services.

## Business Model

The business depends on subscription economics, branded consumer demand, and the ability to expand across adjacent self-pay healthcare categories.

## Landscape Position

Hims is not a biotech name, but it is a fast-growing healthcare platform whose stock reacts to customer growth and monetization.

## Future Catalysts

- Hims & Hers's catalysts are membership growth, weight-loss and primary-care expansion, and whether the platform can keep monetizing its direct-to-consumer health base. The company matters most when new categories turn into recurring subscribers rather than one-time spikes.

## Recent News
- 2026-02-06 01:51 EST — [Hims GLP-1 Weight Loss: What Consumers Should Know About the Reported $49 Compounded Semaglutide Pill, Novo Nordisk Response, and Telehealth Prescription Access in 2026](https://biopharmsignal.com/news/HIMS/hims-glp-1-weight-loss-what-consumers-should-know-about-the-reported-49-compound-4d7ec809) — Source: Hims & Hers